RCRuijun Chen

Ruijun Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ruijun Chen has a total of 334 co-authors. Here are the top co-authors by number of shared publications:

  • Aakriti Gupta

    Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT

    9 shared publications
  • Behnood Bikdeli

    Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT

    9 shared publications
  • Kumar Dharmarajan

    Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT; Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

    8 shared publications
  • George Hripcsak

    Department of Biomedical Informatics, Columbia University Medical Center, New York, New York, USA

    7 shared publications
  • Isuru Ranasinghe

    Department of Cardiology, The Prince Charles Hospital, Brisbane, Australia

    7 shared publications
  • Harlan M. Krumholz

    Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA

    6 shared publications

Latest Publications

  • Open Access

    Research on Translation in Publicity in Cross-cultural Communication-Take Journey to The West as an Example

    by Ruijun Chen

    Journey to the West is one of the four great classical novels in China. It has a fascinating plot and a magic form to represent the struggle between hearts, which has high literary and artistic value. As an excellent traditional cultural masterpiece, Journey to the West can respond to the Sixth Plenary session of the 19th Central Committee to enhance people's cultural confidence, for the new era to create a new situation for the cause of the Party and the country to provide strong spiritual strength. Especially in the context of Chinese culture going out, this masterpiece is of great significance to the external communication of Chinese traditional culture. Based on the names and appellations in different versions of Journey to the West and the translation of poems, this paper analyzes the foreignization and domestication strategies used in different versions of Journey to the West from the perspective of domestication and foreignization, and explores what the translator wants to achieve by using this translation strategy, so as to promote the spread of Journey to the West abroad.

  • Top Cited Papers
    Open Access

    rECHOmmend: An ECG-Based Machine Learning Approach for Identifying Patients at Increased Risk of Undiagnosed Structural Heart Disease Detectable by Echocardiography

    by Alvaro E. Ulloa-Cerna, Linyuan Jing, John M. Pfeifer, Sushravya Raghunath, Jeffrey A. Ruhl, Daniel B. Rocha, Joseph B. Leader, Noah Zimmerman, Greg Lee, Steven R. Steinhubl, et al.

    Background: Timely diagnosis of structural heart disease improves patient outcomes, yet many remain underdiagnosed. While population screening with echocardiography is impractical, electrocardiogram (ECG)-based prediction models can help target high-risk patients. We developed a novel ECG-based machine learning approach to predict multiple structural heart conditions, hypothesizing that a composite model would yield higher prevalence and positive predictive values (PPVs) to facilitate meaningful recommendations for echocardiography. Methods: Using 2,232,130 ECGs linked to electronic health records and echocardiography reports from 484,765 adults between 1984-2021, we trained machine learning models to predict the presence or absence of any of seven echocardiography-confirmed diseases within one year. This composite label included: moderate or severe valvular disease (aortic/mitral stenosis or regurgitation, tricuspid regurgitation), reduced ejection fraction 15mm. We tested various combinations of input features (demographics, labs, structured ECG data, ECG traces) and evaluated model performance using 5-fold cross-validation, multi-site validation trained on one site and tested on 10 independent sites, and simulated retrospective deployment trained on pre-2010 data and deployed in 2010. Results: Our composite 'rECHOmmend' model using age, sex and ECG traces had an area under the receiver operating characteristic curve (AUROC) of 0.91 and PPV of 42% at 90% sensitivity, with a composite label prevalence of 17.9%. Individual disease models had AUROCs from 0.86-0.93 and lower PPVs from 1%-31%. AUROCs for models using different input features ranged from 0.80-0.93, increasing with additional features. Multi-site validation showed similar results to cross-validation, with an aggregate AUROC of 0.91 across our independent test set of 10 clinical sites after training on a separate site. Our simulated retrospective deployment showed that for ECGs acquired in patients without pre-existing structural heart disease in the year 2010, 11% were classified as high-risk, of which 41% (4.5% of total patients) developed true echocardiography-confirmed disease within one year. Conclusions: An ECG-based machine learning model using a composite endpoint can identify a high-risk population for having undiagnosed, clinically significant structural heart disease while outperforming single disease models and improving practical utility with higher PPVs. This approach can facilitate targeted screening with echocardiography to improve under-diagnosis of structural heart disease.


  • Open Access

    rECHOmmend: an ECG-based machine-learning approach for identifying patients at high-risk of undiagnosed structural heart disease detectable by echocardiography

    by Alvaro E. Ulloa-Cerna, Linyuan Jing, John M. Pfeifer, Sushravya Raghunath, Jeffrey A. Ruhl, Daniel B. Rocha, Joseph B. Leader, Noah Zimmerman, Greg Lee, Steven R. Steinhubl, et al.

    Background Early diagnosis of structural heart disease improves patient outcomes, yet many remain underdiagnosed. While population screening with echocardiography is impractical, electrocardiogram (ECG)-based prediction models can help target high-risk patients. We developed a novel ECG-based machine learning approach to predict multiple structural heart conditions, hypothesizing that a composite model would yield higher prevalence and positive predictive values (PPVs) to facilitate meaningful recommendations for echocardiography. Methods Using 2,232,130 ECGs linked to electronic health records and echocardiography reports from 484,765 adults between 1984-2021, we trained machine learning models to predict the presence of any of seven echocardiography-confirmed diseases within one year. This composite label included: moderate or severe valvular disease (aortic/mitral stenosis or regurgitation, tricuspid regurgitation), reduced ejection fraction 15mm. We tested various combinations of input features (demographics, labs, structured ECG data, ECG traces) and evaluated model performance using 5-fold cross-validation, multi-site validation trained on one clinical site and tested on 11 other independent sites, and simulated retrospective deployment trained on pre-2010 data and deployed in 2010. Findings Our composite “rECHOmmend” model using age, sex and ECG traces had an area under the receiver operating characteristic curve (AUROC) of 0.91 and a PPV of 42% at 90% sensitivity at a prevalence of 17.9% for our composite label. Individual disease models had AUROCs ranging from 0.86-0.93 and lower PPVs from 1%-31%. The AUROC for models using different input features ranged from 0.80-0.93, increasing with additional features. Multi-site validation showed similar results to the cross-validation, with an aggregate AUROC of 0.91 across our independent test set of 11 clinical sites after training on a separate site. Our simulated retrospective deployment showed that for ECGs acquired in patients without pre-existing known structural heart disease in a single year, 2010, 11% were classified as high-risk, of which 41% developed true, echocardiography-confirmed disease within one year. Interpretation An ECG-based machine learning model using a composite endpoint can predict previously undiagnosed, clinically significant structural heart disease while outperforming single disease models and improving practical utility with higher PPVs. This approach can facilitate targeted screening with echocardiography to improve under-diagnosis of structural heart disease.

  • Open Access

    RESEARCH PROTOCOL: Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus

    by Rohan Khera, Martijn J Scheumie, Yuan Lu, Anna Ostropolets, Ruijun Chen, George M Hripcsak, Patrick B Ryan, Harlan M Krumholz, Marc A Suchard

    Background: Therapeutic options for type 2 diabetes mellitus (T2DM) have expanded over the last decade with the emergence of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP1) receptor agonists, which reduced the risk of major cardiovascular events in randomized controlled trials (RCTs). Cardiovascular evidence for older second-line agents, such as sulfonylureas, and direct head-to-head comparisons, including with dipeptidyl peptidase 4 (DPP4) inhibitors, are lacking, leaving a critical gap in our understanding of the relative effects of T2DM agents on cardiovascular risk and on patient-centered safety outcomes. Methods and Analysis: The Large-Scale Evidence Generations Across a Network of Databases for T2DM (LEGEND-T2DM) initiative is a series of systematic, large-scale, multinational, real-world comparative cardiovascular effectiveness and safety studies of all 4 major second-line anti-hyperglycemic agents including SGLT2 inhibitor, GLP1 receptor agonist, DPP4 inhibitor and sulfonylureas. LEGEND-T2DM will leverage the Observational Health Data Science and Informatics (OHDSI) community that provides access to a global network of administrative claims and electronic health record (EHR) data sources. Committed data partners represent 190 million patients in the US and about 50 million internationally. LEGEND-T2DM will identify all adult, T2DM patients who newly initiate a traditionally second-line T2DM agent, including individuals with and without established cardiovascular disease. Using an active comparator, new-user cohort design, LEGEND-T2DM will execute all pairwise class-vs-class and drug-vs-drug comparisons in each data source that meet a minimum patient count of 1,000 per arm and extensive study diagnostics that assess reliability and generalizability through cohort balance and equipoise to examine the relative risk of cardiovascular and safety outcomes. The primary cardiovascular outcomes include a 3-point and a 4-point composite of major adverse cardiovascular events, and series of safety outcomes. The study will pursue data-driven, large-scale propensity adjustment for measured confounding, a large set of negative control outcome experiments to address unmeasured and systematic bias. Ethics and Dissemination: The study ensures data safety through a federated analytic approach and follows research best practices, including prespecification and full disclosure of hypotheses tested and their results. LEGEND-T2DM is dedicated to open science and transparency and will publicly share all our analytic code from reproducible cohort definitions through turn-key software, enabling other research groups to leverage our methods, data, and results in order to verify and extend our findings.


  • Data Consult Service: Can we use observational data to address immediate clinical needs?

    by Anna Ostropolets, Philip Zachariah, Patrick Ryan, Ruijun Chen, George Hripcsak

    Objective: A number of clinical decision support tools aim to use observational data to address immediate clinical needs, but few of them address challenges and biases inherent in such data. The goal of this article is to describe the experience of running a data consult service that generates clinical evidence in real time and characterize the challenges related to its use of observational data. Materials and Methods: In 2019, we launched the Data Consult Service pilot with clinicians affiliated with Columbia University Irving Medical Center. We created and implemented a pipeline (question gathering, data exploration, iterative patient phenotyping, study execution, and assessing validity of results) for generating new evidence in real time. We collected user feedback and assessed issues related to producing reliable evidence. Results: We collected 29 questions from 22 clinicians through clinical rounds, emails, and in-person communication. We used validated practices to ensure reliability of evidence and answered 24 of them. Questions differed depending on the collection method, with clinical rounds supporting proactive team involvement and gathering more patient characterization questions and questions related to a current patient. The main challenges we encountered included missing and incomplete data, underreported conditions, and nonspecific coding and accurate identification of drug regimens. Conclusions: While the Data Consult Service has the potential to generate evidence and facilitate decision making, only a portion of questions can be answered in real time. Recognizing challenges in patient phenotyping and designing studies along with using validated practices for observational research are mandatory to produce reliable evidence.


  • Top Cited Papers

    Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study

    by RuiJun Chen, Marc A. Suchard, Harlan M. Krumholz, Martijn J. Schuemie, Steven Shea, Jon Duke, Nicole Pratt, Christian G. Reich, David Madigan, Seng Chan You, et al.

    ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers (ARBs) are equally guideline-recommended first-line treatments for hypertension, yet few head-to-head studies exist. We compared the real-world effectiveness and safety of ACE inhibitors versus ARBs in the first-line treatment of hypertension. We implemented a retrospective, new-user comparative cohort design to estimate hazard ratios using techniques to minimize residual confounding and bias, specifically large-scale propensity score adjustment, empirical calibration, and full transparency. We included all patients with hypertension initiating monotherapy with an ACE inhibitor or ARB between 1996 and 2018 across 8 databases from the United States, Germany, and South Korea. The primary outcomes were acute myocardial infarction, heart failure, stroke, and composite cardiovascular events. We also studied 51 secondary and safety outcomes including angioedema, cough, syncope, and electrolyte abnormalities. Across 8 databases, we identified 2 297 881 patients initiating treatment with ACE inhibitors and 673 938 patients with ARBs. We found no statistically significant difference in the primary outcomes of acute myocardial infarction (hazard ratio, 1.11 for ACE versus ARB [95% CI, 0.95–1.32]), heart failure (hazard ratio, 1.03 [0.87–1.24]), stroke (hazard ratio, 1.07 [0.91–1.27]), or composite cardiovascular events (hazard ratio, 1.06 [0.90–1.25]). Across secondary and safety outcomes, patients on ARBs had significantly lower risk of angioedema, cough, pancreatitis, and GI bleeding. In our large-scale, observational network study, ARBs do not differ statistically significantly in effectiveness at the class level compared with ACE inhibitors as first-line treatment for hypertension but present a better safety profile. These findings support preferentially prescribing ARBs over ACE inhibitors when initiating treatment for hypertension.


  • Comprehensive Comparative Effectiveness and Safety of First-Line β-Blocker Monotherapy in Hypertensive Patients

    by Seng Chan You, Harlan M. Krumholz, Marc A. Suchard, Martijn J. Schuemie, George Hripcsak, RuiJun Chen, Steven Shea, Jon Duke, Nicole Pratt, Christian G. Reich, et al.

    Evidence for the effectiveness and safety of the third-generation β-blockers other than atenolol in hypertension remains scarce. We assessed the effectiveness and safety of β-blockers as first-line treatment for hypertension using 3 databases in the United States: 2 administrative claims databases and 1 electronic health record–based database from 2001 to 2018. In each database, comparative effectiveness of β-blockers for the risks of acute myocardial infarction, stroke, and hospitalization for heart failure was assessed, using large-scale propensity adjustment and empirical calibration. Estimates were combined across databases using random-effects meta-analyses. Overall, 118 133 and 267 891 patients initiated third-generation β-blockers (carvedilol and nebivolol) or atenolol, respectively. The pooled hazard ratios (HRs) of acute myocardial infarction, stroke, hospitalization for heart failure, and most metabolic complications were not different between the third-generation β-blockers versus atenolol after propensity score matching and empirical calibration (HR, 1.07 [95% CI, 0.74–1.55] for acute myocardial infarction; HR, 1.06 [95% CI, 0.87–1.31] for stroke; HR, 1.46 [95% CI, 0.99–2.24] for hospitalized heart failure). Third-generation β-blockers were associated with significantly higher risk of stroke than ACE (angiotensin-converting enzyme) inhibitors (HR, 1.29 [95% CI, 1.03–1.72]) and thiazide diuretics (HR, 1.56 [95% CI, 1.17–2.20]). In conclusion, this study found many patients with first-line β-blocker monotherapy for hypertension and no statistically significant differences in the effectiveness and safety comparing atenolol with third-generation β-blockers. Patients on third-generation β-blockers had a higher risk of stroke than those on ACE inhibitors and thiazide diuretics.


  • Open Access

    Development and validation of prediction models for mechanical ventilation, renal replacement therapy, and readmission in COVID-19 patients

    by Victor Alfonso Rodriguez, Shreyas Bhave, Ruijun Chen, Chao Pang, George Hripcsak, Soumitra Sengupta, Noemie Elhadad, Robert Green, Jason Adelman, Katherine Schlosser Metitiri, et al.

    Objective: Coronavirus disease 2019 (COVID-19) patients are at risk for resource-intensive outcomes including mechanical ventilation (MV), renal replacement therapy (RRT), and readmission. Accurate outcome prognostication could facilitate hospital resource allocation. We develop and validate predictive models for each outcome using retrospective electronic health record data for COVID-19 patients treated between March 2 and May 6, 2020.Materials and Methods: For each outcome, we trained 3 classes of prediction models using clinical data for a cohort of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)–positive patients (n = 2256). Cross-validation was used to select the best-performing models per the areas under the receiver-operating characteristic and precision-recall curves. Models were validated using a held-out cohort (n = 855). We measured each model’s calibration and evaluated feature importances to interpret model output.Results: The predictive performance for our selected models on the held-out cohort was as follows: area under the receiver-operating characteristic curve—MV 0.743 (95% CI, 0.682-0.812), RRT 0.847 (95% CI, 0.772-0.936), readmission 0.871 (95% CI, 0.830-0.917); area under the precision-recall curve—MV 0.137 (95% CI, 0.047-0.175), RRT 0.325 (95% CI, 0.117-0.497), readmission 0.504 (95% CI, 0.388-0.604). Predictions were well calibrated, and the most important features within each model were consistent with clinical intuition.Discussion: Our models produce performant, well-calibrated, and interpretable predictions for COVID-19 patients at risk for the target outcomes. They demonstrate the potential to accurately estimate outcome prognosis in resource-constrained care sites managing COVID-19 patients.Conclusions: We develop and validate prognostic models targeting MV, RRT, and readmission for hospitalized COVID-19 patients which produce accurate, interpretable predictions. Additional external validation studies are needed to further verify the generalizability of our results.


  • Top Cited Papers
    Open Access

    Measurement of clinical documentation burden among physicians and nurses using electronic health records: a scoping review

    by Amanda J Moy, Jessica M Schwartz, RuiJun Chen, Shirin Sadri, Eugene Lucas, Kenrick D Cato, Sarah Collins Rossetti

    Electronic health records (EHRs) are linked with documentation burden resulting in clinician burnout. While clear classifications and validated measures of burnout exist, documentation burden remains ill-defined and inconsistently measured. We aim to conduct a scoping review focused on identifying approaches to documentation burden measurement and their characteristics. Based on Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Extension for Scoping Reviews (ScR) guidelines, we conducted a scoping review assessing MEDLINE, Embase, Web of Science, and CINAHL from inception to April 2020 for studies investigating documentation burden among physicians and nurses in ambulatory or inpatient settings. Two reviewers evaluated each potentially relevant study for inclusion/exclusion criteria. Of the 3482 articles retrieved, 35 studies met inclusion criteria. We identified 15 measurement characteristics, including 7 effort constructs: EHR usage and workload, clinical documentation/review, EHR work after hours and remotely, administrative tasks, cognitively cumbersome work, fragmentation of workflow, and patient interaction. We uncovered 4 time constructs: average time, proportion of time, timeliness of completion, activity rate, and 11 units of analysis. Only 45.0% of studies assessed the impact of EHRs on clinicians and/or patients and 40.0% mentioned clinician burnout. Standard and validated measures of documentation burden are lacking. While time and effort were the core concepts measured, there appears to be no consensus on the best approach nor degree of rigor to study documentation burden. Further research is needed to reliably operationalize the concept of documentation burden, explore best practices for measurement, and standardize its use.


  • Open Access

    Treatment Patterns for Chronic Comorbid Conditions in Patients With Cancer Using a Large-Scale Observational Data Network

    by Ruijun Chen, Patrick Ryan, Karthik Natarajan, Thomas Falconer, Katherine D. Crew, Christian G. Reich, Rohit Vashisht, Gurvaneet Randhawa, Nigam H. Shah, George Hripcsak

    Patients with cancer are predisposed to developing chronic, comorbid conditions that affect prognosis, quality of life, and mortality. While treatment guidelines and care variations for these comorbidities have been described for the general noncancer population, less is known about real-world treatment patterns in patients with cancer. We sought to characterize the prevalence and distribution of initial treatment patterns across a large-scale data network for depression, hypertension, and type II diabetes mellitus (T2DM) among patients with cancer. We used the Observational Health Data Sciences and Informatics network, an international collaborative implementing the Observational Medical Outcomes Partnership Common Data Model to standardize more than 2 billion patient records. For this study, we used 8 databases across 3 countries—the United States, France, and Germany—with 295,529,655 patient records. We identified patients with cancer using SNOMED (Systematized Nomenclature of Medicine) codes validated via manual review. We then characterized the treatment patterns of these patients initiating treatment of depression, hypertension, or T2DM with persistent treatment and at least 365 days of observation. Across databases, wide variations exist in treatment patterns for depression (n = 1,145,510), hypertension (n = 3,178,944), and T2DM (n = 886,766). When limited to 6-node (6-drug) sequences, we identified 61,052 unique sequences for depression, 346,067 sequences for hypertension, and 40,629 sequences for T2DM. These variations persisted across sites, databases, countries, and conditions, with the exception of metformin (73.8%) being the most common initial T2DM treatment. The most common initial medications were sertraline (17.5%) and escitalopram (17.5%) for depression and hydrochlorothiazide (20.5%) and lisinopril (19.6%) for hypertension. We identified wide variations in the treatment of common comorbidities in patients with cancer, similar to the general population, and demonstrate the feasibility of conducting research on patients with cancer across a large-scale observational data network using a common data model.